TriSalus Life Sciences, Inc. is offering shares of its common stock pursuant to a preliminary prospectus supplement dated February 19, 2026. The prospectus supplement supplements a shelf registration and describes the terms and mechanics of a primary offering of Common Stock listed on Nasdaq as "TLSI."
The filing discloses preliminary unaudited financial context: estimated Q4 2025 revenue of $13.2 million, full-year 2025 revenue of $45.2 million, and approximately $20.4 million of cash and cash equivalents as of December 31, 2025. The company states net proceeds will be used for general corporate purposes and that underwriting details, offering price and number of shares are set forth in the prospectus supplement (subject to completion).
TriSalus Life Sciences, Inc. director Michael P. Stansky reported receiving a grant of stock options to buy 92,537 shares of common stock at an exercise price of $4.91 per share. The options vest in three equal annual installments starting on February 4, 2027, contingent on his continued service with the company.